Patents by Inventor Moran RAWET SLOBODKIN

Moran RAWET SLOBODKIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12139522
    Abstract: The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD 138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: November 12, 2024
    Assignees: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEAL SERVICED FUND OF THE TEL AVIV MEDECAL CENTER, YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Zelig Eshhar, Tova Waks, Anat Globerson Levin, Naamit Deshet-Unger, Moran Rawet Slobodkin, Dan Grisaru, Ben Zion Katz, Ido Laskov
  • Publication number: 20240216510
    Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to Sialyl Tn carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.
    Type: Application
    Filed: April 13, 2022
    Publication date: July 4, 2024
    Inventors: Vered PADLER-KARAVANI, Ron AMON, Lihi NINIOMANY, Moran RAWET SLOBODKIN, Anat GLOBERSON LEVIN, Tova WAKS, Zelig ESHHAR
  • Publication number: 20240139247
    Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Inventors: Zelig ESHHAR, Tova WAKS, Anat GLOBERSON LEVIN, Moran RAWET SLOBODKIN
  • Patent number: 11944644
    Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: April 2, 2024
    Assignees: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER, YEDA RESEARCH AND DEVELOPMENT CO. LTD
    Inventors: Zelig Eshhar, Tova Waks, Anat Globerson Levin, Moran Rawet Slobodkin
  • Publication number: 20230058044
    Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to SLe A carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 23, 2023
    Inventors: Vered PADLER-KARAVANI, Yafit ATIYA-NASAGI, Ron AMON, Anat GLOBERSON LEVIN, Tova WAKS, Moran RAWET-SLOBODKIN, Lihi NINIO MANY, Zelig ESHHAR
  • Publication number: 20200384024
    Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
    Type: Application
    Filed: December 4, 2018
    Publication date: December 10, 2020
    Inventors: Zelig ESHHAR, Tova WAKS, Anat GLOBERSON LEVIN, Moran RAWET SLOBODKIN